Skip to main content
Ovoca Bio Plc logo

Ovoca Bio Plc — Investor Relations & Filings

Ticker · OVXA ISIN · IE00B4XVDC01 LEI · 213800ST2AK5XQ1O5207 IR Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2022-07-29 Regulatory Filings
Country IE Ireland
Listing IR OVXA

About Ovoca Bio Plc

https://ovocabio.com/

Ovoca Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. Its lead product candidate is Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack of sexual desire and representing a significant area of high unmet medical need. The company is advancing Orenetide through clinical development for major global markets and has filed for marketing approval in the US and Europe. Ovoca Bio's strategy includes leveraging its patent portfolio and considering licensing or collaboration opportunities to accelerate the availability of its product candidates to patients.

Recent filings

Filing Released Lang Actions
Completion of Enrollment in Phase II Study
Regulatory Filings Classification · 100% confidence The document is a formal announcement released via RNS (RNS Number: 1440U) on July 29, 2022. The content details a specific operational milestone for a biopharmaceutical company (Ovoca Bio PLC): the completion of enrollment in a Phase II clinical study for a drug called Orenetide. This type of announcement, which communicates a specific, time-sensitive operational or clinical update that is not a full financial report (like 10-K or IR) or a general earnings release (ER), fits best under the general category of regulatory announcements or news service releases. Since it is explicitly distributed via RNS and contains information relevant to investors but doesn't fit the more specific categories like DIV, CAP, or ER, the most appropriate classification is Regulatory Filings (RNS). It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Audit Report (AR).
2022-07-29 English
Annual Financial Report
Report Publication Announcement Classification · 100% confidence The document explicitly states, 'Ovoca Bio plc announces the publication of its Annual Report and Financial Statements for the year ended 31 December 2021.' It also contains a 'Letter from the CEO' and a summary of '2021 Highlights,' which are typical components of an Annual Report. However, the document itself is a short regulatory announcement (RNS Number: 7116Q) whose primary function is to inform the market that the full Annual Report has been published and provides a link to it. According to Rule 2 ('MENU VS MEAL' Rule), if the document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). The document length (9275 chars) is substantial but the content is structured as an announcement pointing to the full report, rather than the full report itself (which would typically be classified as 10-K if it were the full statutory filing, or IR if it were a comprehensive interim report). Given the explicit title 'Publication of 2021 Annual Report' and the structure pointing to an external PDF, RPA is the most accurate classification for this announcement.
2022-06-30 English
Statement re Russian Business Operations
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated March 7, 2022. It contains a 'Statement regarding Russian business operations' issued by Ovoca Bio PLC. The text concludes with standard boilerplate language indicating it was provided by 'RNS, the news service of the London Stock Exchange' and is approved by the 'Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since the content is a specific operational update (not a financial report, earnings release, or director dealing), and it is explicitly distributed via RNS, the most appropriate classification is the general regulatory announcement category.
2022-03-07 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 6181C' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, immediate operational announcement related to trading halts or volatility controls. This type of brief, time-sensitive regulatory notification that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory announcement category, RNS (Regulatory Filings). It is not an announcement of a report being published (RPA), but a direct regulatory update.
2022-02-23 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, short announcement related to trading mechanics rather than a comprehensive financial report (like 10-K or IR) or a management change. Given the source (RNS) and the nature of the brief, specific regulatory update, the most appropriate classification is the general regulatory announcement category, RNS.
2022-02-23 English
Russian Marketing Authorisation for Orenetide
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory news service announcement. The content is a press release announcing a Marketing Authorisation approval and ongoing partnership discussions, which is a material event disclosure. Given the source (RNS) and the nature of the announcement (a specific corporate event update rather than a full financial report or a general proxy statement), the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that doesn't fit the more specific categories like ER, 10-K, or DIV. The document length is relatively short (4766 chars), supporting the idea that it is an announcement rather than the full underlying report.
2022-02-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.